Myasthenia Gravis (MS) is a debilitating autoimmune disease affecting the neuromuscular system. In MG, dysregulation of the immune system results in immune mediated destruction of the neuromuscular cells resulting in weakening of the skeletal system. Patients suffering from MG experience symptoms such as fatigue, double vision, and unsteady walking significantly reducing their quality of life.
There is no cure for MG. Treatment options currently available rely on chronic immune suppression which do not address immunological drivers of disease and expose patients to toxic side effects.
CNP-MYG is the only antigen specific treatment option which can prevent immune mediated neuromuscular destruction. CNP-MYG specifically targets the pathological components of the immune system driving disease pathology while leaving beneficial immune repair mechanisms intact. CNP-MYG can not only prevent tissue damage but also enable functional recovery without causing toxic side effects.